Price$1255.20+7.00 (+0.56%)
01:30 PM07:45 PM
News · 26 weeks103+45%
2026-03-012026-08-23
Mix5090d
- Other26(52%)
- Insider17(34%)
- SEC Filings3(6%)
- Earnings2(4%)
- Dividends1(2%)
- Leadership1(2%)
Latest news
25 items- PRMost AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.NEW YORK, Aug. 19, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - Artificial intelligence has become the most talked-about tool in drug discovery, promising to compress the years and billions of dollars it takes to turn a biological insight into a medicine. But most of the AI now aimed at biology shares a hidden limitation: it reasons primarily from sequence, the raw genetic letters of DNA, RNA, and proteins. Two molecules whose sequences look alike are treated as related; two that look different are treated as unrelated. That assumption is convenient, and it is often wrong, because biology repeatedly reaches the same function through completely different-looking structures. A c
- INSIDERDirector Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,004 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Luciano Juan R was granted 13 shares, increasing direct ownership by 0.08% to 16,918 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Fyrwald J Erik was granted 8 shares, increasing direct ownership by 0.01% to 75,418 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Alvarez Ralph was granted 10 shares, increasing direct ownership by 0.02% to 55,745 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDEREVP & President, LLY Int'l Jonsson Patrik sold $7,638,150 worth of shares (6,500 units at $1,175.10) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 54,147 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- PRA New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.Issued on behalf of Conexeu Sciences Inc. NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - For as long as aesthetic medicine has existed, its central promise has been to replace what time and gravity take away: fill a wrinkle, restore lost volume, reshape a contour. Now a shift in the underlying science is pointing toward something more ambitious. Instead of simply replacing volume, a growing body of research is asking whether the body's own tissue can be prompted to rebuild itself, and a new commercial category is beginning to form around that idea. At the center of the science is a structure most people have never heard of, the extracellular matrix, the frame
- PRThe GLP-1 Boom Created a Tissue Gap Fillers Were Not Built ForRENO, Nev., Aug. 12, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - The weight-loss drug boom has been one of the defining healthcare stories of the decade, and its success has created a second-order opportunity that the drugs themselves were never designed to address. Rapid, large-volume weight loss does not only remove fat. It leaves behind slackened skin and hollowed facial and body contours that conventional dermal fillers and injectables, built for fine lines and modest volume, were never engineered to address. On August 3, 2026, Conexeu Sciences Inc. (NASDAQ:CNXU) President and Chief Executive Officer Miles Harrison sat down with IPO Edge for a fireside chat that put that
- PRLilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black marketFiles six new lawsuits as company escalates fight to protect patientsINDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S. entities selling black-market products in addition to having referred hundreds of bad actors to regulators and law enforcement worldwide. Lilly is also calling on the entities that sellers use to conduct their illegal business—social media and e-commerce platforms, credit card companies, payment processors and shipping and logistics carriers—to help protect patients and fight this illicit activity. According
- INSIDERSVP, Finance, & CAO Zakrowski Donald A sold $2,370,020 worth of shares (2,000 units at $1,185.01) as part of a pre-agreed trading plan, decreasing direct ownership by 57% to 1,526 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDEREVP, GC & Secretary Hakim Anat sold $5,950,000 worth of shares (5,000 units at $1,190.00) as part of a pre-agreed trading plan (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- SECSEC Form 10-Q filed by Eli Lilly and Company10-Q - ELI LILLY & Co (0000059478) (Filer)
- SECEli Lilly and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ELI LILLY & Co (0000059478) (Filer)
- PRLilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progressRevenue in Q2 2026 increased 48% to $23.0 billion driven primarily by Mounjaro and Zepbound volume.Q2 2026 EPS increased by 26% to $7.94 on a reported basis and increased by 33% to $8.38 on a non-GAAP basis. Q2 2026 reported and non-GAAP EPS included $3.03 of acquired IPR&D charges compared to $0.14 in Q2 2025.Increased 2026 full-year revenue guidance to be in the range of $85.0 billion to $87.0 billion and raised underlying non-GAAP EPS guidance for the full year by $2.78 at the midpoint, which was more than offset by $3.03 of acquired IPR&D charges from Q2 business development activity, resulting in an updated range of $35.50 to $36.50. Regulatory progress included U.S. FDA approval of Eb
- INSIDEREVP, Global Quality Seymour Melissa converted options into 981 shares and covered exercise/tax liability with 439 shares, increasing direct ownership by 103% to 1,067 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- PRLilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancerINDIANAPOLIS, Aug. 3, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer who have received at least one prior systemic therapy and have a KRAS G12C mutation, as determined by an FDA-approved test. Olomorasib is an investigational, potent and highly selective next-generation inhibitor of KRAS G12C. Olomorasib was previously granted Breakthrough Therapy designation, in combination with anti-PD-1 therapy KEYTRUDA (pembrolizumab), for the first-line treatment of patients with locally adv
- INSIDERNew insider Eli Lilly & Co claimed ownership of 1,054,828 shares (SEC Form 3)3 - ELI LILLY & Co (0000059478) (Reporting)
- PRLilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1CIn TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeksIn TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost up to an average of 55.8 lbs (22.6%) at 80 weeksLilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027INDIANAPOLIS, July 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutid
- PRLilly confirms date and conference call for second-quarter 2026 financial results announcementINDIANAPOLIS, July 22, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its second-quarter 2026 financial results on August 5, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call. About LillyLilly is a medicine company turning science into heali
- INSIDERDirector Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,000 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,905 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Fyrwald J Erik was granted 9 shares, increasing direct ownership by 0.01% to 75,410 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Alvarez Ralph was granted 11 shares, increasing direct ownership by 0.02% to 55,734 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- PRBillions Flow Into Next-Generation Depression Treatments as Pharma Innovation AcceleratesMajor Depressive Disorder Market Poised for Strong Growth as New Drug Innovations Transform Patient CareNEW YORK, July 21, 2026 /CNW/ -- Market News UpdatesNews Commentary - Globally, Major Depressive Disorder (MDD) is a prevalent mental health condition that has seen an improvement in patient outcomes due to new approaches introduced by pharmaceutical companies. Traditionally, treatments focused on boosting serotonin levels or other neurotransmitters, resulting in long waiting periods for patients to notice any changes, without any assurance of effectiveness. However, there is now a shift towards quicker-acting medications, exploration of new biological targets, and the development of perso
- PRBig Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real TimeIssued on behalf of Helus Pharma™Eli Lilly's agreement to acquire AtaiBeckley for up to $3.8 billion hands psychedelic medicine its first large-cap validation, and it lands on a late-stage cohort already carrying pivotal data into the back half of 2026, among them Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), which has a Phase 3 readout due in the fourth quarterUSA News Group News CommentaryNEW YORK, July 17, 2026 /CNW/ -- For half a century, psychedelic medicine was the field serious money would not touch. That ended this morning. Eli Lilly and Company (NYSE:LLY) agreed to acquire AtaiBeckley Inc. (NASDAQ:ATAI) for $6.75 per share in cash, roughly $2.8 billion, plus up to $2.50 per share in
LLY FAQ
7 questionsWhat does Eli Lilly and Company do?
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer...Where does LLY stock trade?
Eli Lilly and Company (LLY) is listed on NYSE.What sector and industry is LLY in?
Eli Lilly and Company operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.Does LLY pay a dividend?
LLY's most recent ex-dividend date was 2026-08-14 with a cash dividend of $1.73 per share. No future ex-date is on file yet.What are analysts saying about LLY?
Eli Lilly and Company has had 8 recent analyst actions on file. The most recent action was from HSBC Securities: Reduce on 2026-03-17.What companies are similar to LLY?
Notable peers in the same industry include ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), AZN (AstraZeneca PLC), PFE (Pfizer Inc.), GSK (GSK plc). Compare LLY side-by-side with any of them on Quantisnow.How can I track LLY on Quantisnow?
Quantisnow aggregates Eli Lilly and Company's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LLY to receive live email and push alerts on every new disclosure.